Summit Therapeutics Inc. — Form 8-K
Filed September 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Akeso Inc. announced that ivonescimab (AK112/SMT112) achieved statistically significant overall survival improvement versus pembrolizumab monotherapy in the Phase III HARMONi-2 study in PD-L1-positive advanced NSCLC patients in China. This is a secondary endpoint read-out; the primary endpoint (PFS by IRRC) previously showed HR 0.51 (95% CI: 0.38, 0.69; p<0.0001). Akeso received NMPA marketing authorization in April 2025. Summit is conducting parallel HARMONi-7 (monotherapy, PD-L1 high) and HARMONi trials in its licensed territories (US, Europe, etc.); HARMONi BLA was submitted to FDA in January 2026 with PDUFA date November 14, 2026.
Why this rating
Ivonescimab is Summit's core late-stage asset. OS benefit validates monotherapy potential; HARMONi BLA pending with FDA approval expected ~8 months away. Strong China data de-risks US/EU program but regulatory approval still uncertain. Meaningful catalyst for $2.5B company.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $15.34 ▲ 5.06% | at our read · unknown $14.60 | +10 min · unknown $15.78 ▲ 8.11% | +30 min · unknown $16.01 ▲ 9.66% | +1 hr pending | +4 hrs pending |
The stock had already moved -4.82% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.